Table 1.

Patients’ demographics (infused patients, N = 9)

Baseline characteristics	Patient A	Patient B	Patient C	Patient D	Patient E	Patient F	Patient G	Patient H	Patient I
Age, years/sex	45/F	65/M	73/F	41/M	69/M	70/F	61/F	32/M	58/M
Prior HSCT	Yes	No	No	Yes	No	No	Yes	No	Yes
Histology review	DLBCL	Othera	DLBCL	DLBCL	DLBCL	tMALT lymphoma	DLBCL	DLBCL	DLBCL
Cell of originb	ABC	NA	ABC	ABC	GCB	ABC	GCB	ABC	ABC
Previous lines of therapies	4	2	3	2	3	5	2	2	3
Disease status at the start of the trial	Relapsed	Relapsed	Relapsed	Relapsed	Relapsed	Refractory	Relapsed	Relapsed	Refractory
Double/triple hits	Negative	NA	Negative	Negative	Negative	Negative	Negative	MYC + BCL6 + rearrangements	NA
Bridging chemotherapy prior to infusion	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No
Investigator-assessed overall response prior to infusion	CR	SD	PD	PD	SD	PR	SD	PD	SD
LDH (U/L) prior to infusionc	144	331 H	222	264 H	497 H	202	261 H	510 H	354 H

ABC activated B cell, DLBCL diffuse large B-cell lymphoma, F female, GCB germinal center B cell, HSCT hematopoietic stem cell transplant, LDH lactate dehydrogenase, M male, NA not available, tMALT transformed mucosa-associated lymphoid tissue

^aNeuroendocrine carcinoma

^bChoi and modified Choi algorithms and Tally method

^cH denotes a value above the upper limit of normal